Network meta-analysis
Diabetic retinopathy complications
Type 2 diabetes (adults)
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
16
Randomized trials
24
Treatments
39,451
Participants
763
Events
In plain language
Across 16 trials with 39,451 participants, 0 of 23 treatments had a clearly better result than placebo on diabetic retinopathy complications, and for 23 the evidence could not tell them apart from placebo. The most favorable estimate was for standard care or no added treatment: hazard ratio (from event counts) 0.35 (95% credible interval 0.00 to 16.62).
- Standard care or no added treatment: not convincingly different from placebo (certainty pending).
- Semaglutide 8 mg injection once weekly: not convincingly different from placebo (certainty pending).
- Semaglutide 2.0 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Exenatide 10 ug subcutaneous twice daily: not convincingly different from placebo (certainty pending).
- Empagliflozin: not convincingly different from placebo (certainty pending).
- Ecnoglutide 1.2 mg injection once weekly: not convincingly different from placebo (certainty pending).
- Ecnoglutide 0.4 mg injection once weekly: not convincingly different from placebo (certainty pending).
- Ecnoglutide 0.8 mg injection once weekly: not convincingly different from placebo (certainty pending).
- Tirzepatide 15 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Tirzepatide 1 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Albiglutide flexible dose injection once weekly: not convincingly different from placebo (certainty pending).
- Liraglutide 1.8 mg subcutaneous once daily: not convincingly different from placebo (certainty pending).
- Dulaglutide 0.75 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Dulaglutide 1.5 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Tirzepatide 10 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Semaglutide 1.0 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Semaglutide 14 mg oral once daily (original tablet): not convincingly different from placebo (certainty pending).
- Semaglutide 0.5 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Semaglutide 7 mg oral once daily (original tablet): not convincingly different from placebo (certainty pending).
- Semaglutide 3 mg oral once daily (original tablet): not convincingly different from placebo (certainty pending).
- Tirzepatide 5 mg subcutaneous once weekly: not convincingly different from placebo (certainty pending).
- Sitagliptin: not convincingly different from placebo (certainty pending).
- Semaglutide 16 mg injection once weekly: not convincingly different from placebo (certainty pending).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Hazard ratio (from event counts). Lower values favor the treatment.
| Treatment | Bayesian HR (95% CrI) | 95% prediction interval | Frequentist HR (95% CI) | Verdict | Confidence |
|---|---|---|---|---|---|
| Standard care or no added treatment STANDARD_CARE | 0.35 (0.00 to 16.62) | 0.00 to 17.81 | Unclear | pending | |
| Semaglutide 8 mg injection once weekly SEMA_SC_8MG_QW | 0.39 (0.01 to 16.20) | 0.01 to 17.34 | Unclear | pending | |
| Semaglutide 2.0 mg subcutaneous once weekly SEMA_SC_2p0MG_QW | 0.41 (0.01 to 16.37) | 0.00 to 17.97 | Unclear | pending | |
| Exenatide 10 ug subcutaneous twice daily EXEN_SC_10UG_BID | 0.50 (0.01 to 48.90) | 0.00 to 51.30 | Unclear | pending | |
| Empagliflozin EMPAGLIFLOZIN | 0.55 (0.11 to 2.53) | 0.10 to 2.89 | Unclear | pending | |
| Ecnoglutide 1.2 mg injection once weekly ECNO_SC_1p2MG_QW | 0.64 (0.01 to 46.99) | 0.01 to 52.86 | Unclear | pending | |
| Ecnoglutide 0.4 mg injection once weekly ECNO_SC_0p4MG_QW | 0.64 (0.01 to 42.82) | 0.01 to 45.49 | Unclear | pending | |
| Ecnoglutide 0.8 mg injection once weekly ECNO_SC_0p8MG_QW | 0.64 (0.01 to 45.64) | 0.01 to 49.07 | Unclear | pending | |
| Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW | 0.66 (0.10 to 3.40) | 0.09 to 3.88 | Unclear | pending | |
| Tirzepatide 1 mg subcutaneous once weekly TIRZ_SC_1MG_QW | 0.70 (0.01 to 42.79) | 0.01 to 45.68 | Unclear | pending | |
| Albiglutide flexible dose injection once weekly ALBI_SC_FLEX_30-50_QW | 0.88 (0.42 to 1.82) | 0.33 to 2.42 | Unclear | pending | |
| Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD | 1.07 (0.53 to 1.87) | 0.41 to 2.56 | Unclear | pending | |
| Dulaglutide 0.75 mg subcutaneous once weekly DULA_SC_0p75MG_QW | 1.08 (0.19 to 5.38) | 0.17 to 6.19 | Unclear | pending | |
| Dulaglutide 1.5 mg subcutaneous once weekly DULA_SC_1p5MG_QW | 1.23 (0.59 to 2.50) | 0.45 to 3.26 | Unclear | pending | |
| Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW | 1.38 (0.28 to 5.81) | 0.26 to 6.71 | Unclear | pending | |
| Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW | 1.50 (0.66 to 3.01) | 0.53 to 3.97 | Unclear | pending | |
| Semaglutide 14 mg oral once daily (original tablet) SEMA_PO_14MG_QD | 1.55 (0.53 to 4.63) | 0.44 to 5.61 | Unclear | pending | |
| Semaglutide 0.5 mg subcutaneous once weekly SEMA_SC_0p5MG_QW | 1.91 (0.93 to 4.22) | 0.74 to 5.65 | Unclear | pending | |
| Semaglutide 7 mg oral once daily (original tablet) SEMA_PO_7MG_QD | 2.00 (0.57 to 7.10) | 0.47 to 8.14 | Unclear | pending | |
| Semaglutide 3 mg oral once daily (original tablet) SEMA_PO_3MG_QD | 2.05 (0.60 to 7.09) | 0.50 to 8.10 | Unclear | pending | |
| Tirzepatide 5 mg subcutaneous once weekly TIRZ_SC_5MG_QW | 2.35 (0.48 to 10.40) | 0.43 to 12.29 | Unclear | pending | |
| Sitagliptin SITAGLIPTIN | 2.66 (0.69 to 9.77) | 0.60 to 11.20 | Unclear | pending | |
| Semaglutide 16 mg injection once weekly SEMA_SC_16MG_QW | 4.89 (0.17 to 137) | 0.16 to 146 | Unclear | pending |
Confidence in the results
How much each comparison can be trusted, rated with CINeMA in six domains and summarized with GRADE.
| Comparison | Within study bias | Reporting bias | Indirectness | Imprecision | Heterogeneity | Incoherence | Confidence |
|---|---|---|---|---|---|---|---|
| Albiglutide flexible dose injection once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Placebo | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Placebo | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Placebo | pending | none | pending | some | some | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Sitagliptin versus Placebo | pending | none | pending | major | none | none | pending |
| Standard care or no added treatment versus Placebo | pending | none | pending | major | none | none | pending |
| Tirzepatide 1 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Tirzepatide 5 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Tirzepatide 10 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
| Tirzepatide 15 mg subcutaneous once weekly versus Placebo | pending | none | pending | major | none | none | pending |
Every other comparison (253)
| Comparison | Within study bias | Reporting bias | Indirectness | Imprecision | Heterogeneity | Incoherence | Confidence |
|---|---|---|---|---|---|---|---|
| Albiglutide flexible dose injection once weekly versus Dulaglutide 0.75 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Dulaglutide 1.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Dulaglutide 1.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Ecnoglutide 0.4 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Ecnoglutide 0.4 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Ecnoglutide 0.4 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Ecnoglutide 0.8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Ecnoglutide 0.8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Ecnoglutide 0.8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Ecnoglutide 0.8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Ecnoglutide 1.2 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Ecnoglutide 1.2 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Ecnoglutide 1.2 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Ecnoglutide 1.2 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Ecnoglutide 1.2 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Empagliflozin | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Empagliflozin | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Empagliflozin | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Empagliflozin | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Empagliflozin | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Empagliflozin | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Exenatide 10 ug subcutaneous twice daily | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Liraglutide 1.8 mg subcutaneous once daily | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | some | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 3 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | some | some | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 7 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | some | some | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 14 mg oral once daily (original tablet) | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 0.5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Semaglutide 1.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Semaglutide 2.0 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Semaglutide 8 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Semaglutide 16 mg injection once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Sitagliptin | pending | none | pending | some | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Sitagliptin | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Sitagliptin versus Standard care or no added treatment | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Sitagliptin versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Standard care or no added treatment versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Tirzepatide 10 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Tirzepatide 15 mg subcutaneous once weekly versus Tirzepatide 1 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Sitagliptin versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Standard care or no added treatment versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Tirzepatide 1 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Tirzepatide 10 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Tirzepatide 15 mg subcutaneous once weekly versus Tirzepatide 5 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Sitagliptin versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Standard care or no added treatment versus Tirzepatide 10 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Albiglutide flexible dose injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 0.75 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Dulaglutide 1.5 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.4 mg injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 0.8 mg injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Ecnoglutide 1.2 mg injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Empagliflozin versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Exenatide 10 ug subcutaneous twice daily versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Liraglutide 1.8 mg subcutaneous once daily versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 3 mg oral once daily (original tablet) versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 7 mg oral once daily (original tablet) versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 14 mg oral once daily (original tablet) versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 0.5 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 1.0 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 2.0 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 8 mg injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Semaglutide 16 mg injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Sitagliptin versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Standard care or no added treatment versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
| Tirzepatide 10 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly | pending | none | pending | major | none | none | pending |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
Rank probabilities
| Treatment | Rank 1 | Rank 2 | Rank 3 | Rank 4 | Rank 5 | Rank 6 | Rank 7 | Rank 8 | Rank 9 | Rank 10 | Rank 11 | Rank 12 | Rank 13 | Rank 14 | Rank 15 | Rank 16 | Rank 17 | Rank 18 | Rank 19 | Rank 20 | Rank 21 | Rank 22 | Rank 23 | Rank 24 | Mean rank |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMPAGLIFLOZIN | 1% | 5% | 8% | 12% | 13% | 13% | 10% | 8% | 6% | 4% | 3% | 3% | 3% | 2% | 2% | 2% | 1% | 1% | 1% | 7.3 | |||||
| STANDARD_CARE | 14% | 13% | 11% | 8% | 8% | 5% | 4% | 3% | 2% | 2% | 2% | 1% | 1% | 2% | 2% | 1% | 2% | 2% | 2% | 2% | 3% | 3% | 4% | 4% | 8.2 |
| SEMA_SC_8MG_QW | 13% | 13% | 11% | 8% | 7% | 5% | 4% | 3% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 4% | 4% | 3% | 8.6 |
| SEMA_SC_2p0MG_QW | 13% | 12% | 11% | 9% | 7% | 5% | 4% | 3% | 2% | 2% | 2% | 2% | 1% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 4% | 5% | 3% | 8.7 |
| TIRZ_SC_15MG_QW | 2% | 4% | 7% | 10% | 11% | 10% | 9% | 7% | 5% | 4% | 4% | 3% | 3% | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 2% | 1% | 8.7 | ||
| ALBI_SC_FLEX_30-50_QW | 1% | 3% | 6% | 9% | 12% | 13% | 12% | 10% | 8% | 7% | 5% | 4% | 3% | 2% | 2% | 1% | 1% | 1% | 9.6 | ||||||
| EXEN_SC_10UG_BID | 13% | 11% | 10% | 8% | 6% | 5% | 4% | 3% | 2% | 2% | 2% | 2% | 2% | 2% | 1% | 1% | 2% | 2% | 2% | 3% | 3% | 4% | 6% | 8% | 9.9 |
| PLACEBO | 1% | 3% | 6% | 10% | 15% | 16% | 15% | 12% | 9% | 5% | 3% | 2% | 1% | 1% | 10.6 | ||||||||||
| ECNO_SC_1p2MG_QW | 11% | 10% | 9% | 8% | 6% | 5% | 4% | 3% | 2% | 2% | 1% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 3% | 5% | 6% | 9% | 10.6 |
| ECNO_SC_0p8MG_QW | 10% | 10% | 9% | 7% | 6% | 5% | 4% | 3% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 5% | 7% | 9% | 10.6 |
| ECNO_SC_0p4MG_QW | 11% | 10% | 9% | 7% | 6% | 5% | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 4% | 5% | 7% | 8% | 10.6 |
| TIRZ_SC_1MG_QW | 11% | 10% | 8% | 7% | 6% | 4% | 4% | 3% | 2% | 2% | 2% | 1% | 2% | 1% | 2% | 2% | 2% | 2% | 2% | 3% | 4% | 5% | 7% | 9% | 10.9 |
| LIRA_SC_1p8MG_QD | 1% | 2% | 3% | 6% | 8% | 10% | 12% | 12% | 12% | 9% | 8% | 6% | 4% | 3% | 2% | 1% | 1% | 11.3 | |||||||
| DULA_SC_0p75MG_QW | 1% | 3% | 5% | 6% | 7% | 7% | 6% | 6% | 5% | 5% | 4% | 5% | 5% | 5% | 5% | 5% | 5% | 4% | 3% | 3% | 2% | 1% | 1% | 11.7 | |
| DULA_SC_1p5MG_QW | 1% | 3% | 3% | 5% | 7% | 8% | 9% | 10% | 10% | 10% | 8% | 7% | 5% | 4% | 3% | 3% | 2% | 1% | 12.9 | ||||||
| TIRZ_SC_10MG_QW | 1% | 2% | 4% | 5% | 5% | 6% | 5% | 5% | 5% | 5% | 5% | 5% | 6% | 5% | 6% | 5% | 6% | 6% | 5% | 5% | 3% | 1% | 13.7 | ||
| SEMA_SC_1p0MG_QW | 1% | 2% | 2% | 3% | 5% | 7% | 7% | 9% | 10% | 10% | 10% | 9% | 8% | 6% | 5% | 3% | 1% | 1% | 14.7 | ||||||
| SEMA_PO_14MG_QD | 1% | 1% | 2% | 3% | 4% | 5% | 5% | 7% | 8% | 9% | 9% | 10% | 10% | 9% | 8% | 5% | 3% | 1% | 14.7 | ||||||
| SEMA_PO_7MG_QD | 1% | 1% | 2% | 2% | 2% | 3% | 4% | 4% | 5% | 6% | 8% | 9% | 10% | 10% | 11% | 10% | 6% | 3% | 1% | 16.9 | |||||
| SEMA_SC_0p5MG_QW | 1% | 1% | 1% | 2% | 2% | 4% | 6% | 6% | 9% | 10% | 11% | 10% | 10% | 9% | 8% | 6% | 3% | 1% | 17.0 | ||||||
| SEMA_PO_3MG_QD | 1% | 1% | 2% | 2% | 2% | 3% | 4% | 4% | 5% | 6% | 7% | 8% | 10% | 11% | 11% | 10% | 8% | 3% | 1% | 17.2 | |||||
| TIRZ_SC_5MG_QW | 1% | 1% | 2% | 2% | 2% | 2% | 3% | 3% | 3% | 3% | 4% | 5% | 5% | 6% | 6% | 7% | 8% | 10% | 11% | 11% | 6% | 17.5 | |||
| SEMA_SC_16MG_QW | 1% | 1% | 1% | 2% | 2% | 3% | 2% | 2% | 2% | 1% | 2% | 1% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 4% | 6% | 9% | 16% | 31% | 18.8 |
| SITAGLIPTIN | 1% | 1% | 1% | 1% | 2% | 3% | 3% | 4% | 4% | 6% | 7% | 10% | 12% | 13% | 15% | 11% | 5% | 19.1 |
League table
Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | STANDARD_CARE | SEMA_SC_8MG_QW | SEMA_SC_2p0MG_QW | EXEN_SC_10UG_BID | EMPAGLIFLOZIN | ECNO_SC_1p2MG_QW | ECNO_SC_0p4MG_QW | ECNO_SC_0p8MG_QW | TIRZ_SC_15MG_QW | TIRZ_SC_1MG_QW | ALBI_SC_FLEX_30-50_QW | LIRA_SC_1p8MG_QD | DULA_SC_0p75MG_QW | DULA_SC_1p5MG_QW | TIRZ_SC_10MG_QW | SEMA_SC_1p0MG_QW | SEMA_PO_14MG_QD | SEMA_SC_0p5MG_QW | SEMA_PO_7MG_QD | SEMA_PO_3MG_QD | TIRZ_SC_5MG_QW | SITAGLIPTIN | SEMA_SC_16MG_QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 2.86 0.06 to 211 | 2.55 0.06 to 188 | 2.47 0.06 to 187 | 2.02 0.02 to 197 | 1.82 0.40 to 8.96 | 1.57 0.02 to 182 | 1.57 0.02 to 159 | 1.55 0.02 to 141 | 1.52 0.29 to 10.32 | 1.44 0.02 to 171 | 1.14 0.55 to 2.36 | 0.93 0.54 to 1.87 | 0.93 0.19 to 5.29 | 0.81 0.40 to 1.71 | 0.72 0.17 to 3.51 | 0.67 0.33 to 1.51 | 0.64 0.22 to 1.88 | 0.52 0.24 to 1.08 | 0.50 0.14 to 1.76 | 0.49 0.14 to 1.68 | 0.43 0.10 to 2.09 | 0.38 0.10 to 1.44 | 0.20 0.01 to 5.72 |
| STANDARD_CARE | 0.35 0.00 to 16.62 | STANDARD_CARE | 0.89 0.00 to 366 | 0.91 0.00 to 269 | 0.69 0.00 to 239 | 0.65 0.01 to 46.29 | 0.55 0.00 to 252 | 0.56 0.00 to 206 | 0.56 0.00 to 214 | 0.55 0.01 to 40.47 | 0.52 0.00 to 229 | 0.39 0.01 to 19.82 | 0.33 0.00 to 16.37 | 0.34 0.00 to 24.03 | 0.29 0.00 to 15.81 | 0.26 0.00 to 17.46 | 0.24 0.00 to 12.50 | 0.23 0.00 to 13.02 | 0.18 0.00 to 9.99 | 0.18 0.00 to 10.36 | 0.17 0.00 to 10.05 | 0.15 0.00 to 10.42 | 0.13 0.00 to 8.31 | 0.07 0.00 to 12.53 |
| SEMA_SC_8MG_QW | 0.39 0.01 to 16.20 | 1.12 0.00 to 333 | SEMA_SC_8MG_QW | 1.02 0.00 to 219 | 0.79 0.00 to 238 | 0.72 0.01 to 44.83 | 0.62 0.00 to 252 | 0.59 0.00 to 225 | 0.63 0.00 to 197 | 0.62 0.01 to 38.30 | 0.58 0.00 to 225 | 0.45 0.01 to 19.54 | 0.37 0.00 to 16.34 | 0.37 0.00 to 22.62 | 0.32 0.00 to 13.88 | 0.28 0.00 to 15.60 | 0.27 0.00 to 11.66 | 0.25 0.00 to 12.11 | 0.21 0.00 to 9.35 | 0.20 0.00 to 10.44 | 0.19 0.00 to 9.65 | 0.17 0.00 to 9.98 | 0.15 0.00 to 7.98 | 0.09 0.00 to 5.64 |
| SEMA_SC_2p0MG_QW | 0.41 0.01 to 16.37 | 1.10 0.00 to 298 | 0.99 0.00 to 264 | SEMA_SC_2p0MG_QW | 0.80 0.00 to 336 | 0.74 0.01 to 47.25 | 0.65 0.00 to 225 | 0.67 0.00 to 242 | 0.61 0.00 to 254 | 0.63 0.01 to 41.51 | 0.58 0.00 to 230 | 0.45 0.01 to 21.14 | 0.38 0.01 to 16.77 | 0.39 0.00 to 24.14 | 0.33 0.00 to 15.08 | 0.30 0.00 to 18.65 | 0.27 0.00 to 12.57 | 0.25 0.00 to 12.71 | 0.21 0.00 to 9.61 | 0.20 0.00 to 10.29 | 0.20 0.00 to 9.72 | 0.17 0.00 to 10.37 | 0.15 0.00 to 8.24 | 0.09 0.00 to 6.61 |
| EXEN_SC_10UG_BID | 0.50 0.01 to 48.90 | 1.44 0.00 to 587 | 1.26 0.00 to 634 | 1.25 0.00 to 581 | EXEN_SC_10UG_BID | 0.92 0.01 to 116 | 0.81 0.00 to 689 | 0.82 0.00 to 421 | 0.80 0.00 to 515 | 0.80 0.01 to 108 | 0.77 0.00 to 490 | 0.56 0.01 to 60.25 | 0.47 0.00 to 48.53 | 0.47 0.00 to 57.90 | 0.40 0.00 to 42.73 | 0.36 0.00 to 46.43 | 0.34 0.00 to 33.84 | 0.32 0.00 to 33.08 | 0.25 0.00 to 25.78 | 0.25 0.00 to 28.99 | 0.24 0.00 to 27.69 | 0.21 0.00 to 26.19 | 0.19 0.00 to 21.11 | 0.10 0.00 to 29.26 |
| EMPAGLIFLOZIN | 0.55 0.11 to 2.53 | 1.54 0.02 to 137 | 1.40 0.02 to 143 | 1.34 0.02 to 132 | 1.09 0.01 to 135 | EMPAGLIFLOZIN | 0.86 0.01 to 118 | 0.85 0.01 to 120 | 0.86 0.01 to 109 | 0.85 0.09 to 9.92 | 0.79 0.01 to 113 | 0.62 0.11 to 3.23 | 0.52 0.11 to 2.45 | 0.50 0.08 to 3.32 | 0.45 0.08 to 2.34 | 0.40 0.05 to 3.50 | 0.37 0.07 to 2.10 | 0.35 0.10 to 1.10 | 0.29 0.05 to 1.51 | 0.27 0.07 to 1.09 | 0.27 0.06 to 1.03 | 0.23 0.03 to 2.04 | 0.21 0.05 to 0.88 | 0.11 0.00 to 4.35 |
| ECNO_SC_1p2MG_QW | 0.64 0.01 to 46.99 | 1.82 0.00 to 828 | 1.63 0.00 to 694 | 1.55 0.00 to 683 | 1.23 0.00 to 753 | 1.16 0.01 to 126 | ECNO_SC_1p2MG_QW | 1.02 0.00 to 489 | 0.99 0.00 to 443 | 0.98 0.01 to 119 | 0.92 0.00 to 463 | 0.71 0.01 to 56.15 | 0.60 0.01 to 48.48 | 0.61 0.00 to 64.91 | 0.51 0.00 to 41.00 | 0.46 0.00 to 48.46 | 0.42 0.00 to 33.69 | 0.41 0.00 to 34.24 | 0.33 0.00 to 26.29 | 0.32 0.00 to 27.36 | 0.31 0.00 to 26.56 | 0.27 0.00 to 28.02 | 0.24 0.00 to 20.59 | 0.12 0.00 to 28.89 |
| ECNO_SC_0p4MG_QW | 0.64 0.01 to 42.82 | 1.78 0.00 to 708 | 1.70 0.00 to 607 | 1.50 0.00 to 690 | 1.22 0.00 to 564 | 1.17 0.01 to 104 | 0.98 0.00 to 527 | ECNO_SC_0p4MG_QW | 1.00 0.00 to 402 | 0.98 0.01 to 108 | 0.92 0.00 to 510 | 0.73 0.01 to 51.60 | 0.60 0.01 to 43.09 | 0.60 0.00 to 55.86 | 0.52 0.00 to 36.94 | 0.47 0.00 to 41.38 | 0.42 0.00 to 31.10 | 0.41 0.00 to 30.70 | 0.34 0.00 to 24.04 | 0.32 0.00 to 25.43 | 0.32 0.00 to 24.28 | 0.27 0.00 to 23.49 | 0.24 0.00 to 20.98 | 0.13 0.00 to 29.25 |
| ECNO_SC_0p8MG_QW | 0.64 0.01 to 45.64 | 1.79 0.00 to 692 | 1.58 0.01 to 588 | 1.64 0.00 to 573 | 1.24 0.00 to 659 | 1.16 0.01 to 110 | 1.01 0.00 to 532 | 1.00 0.00 to 463 | ECNO_SC_0p8MG_QW | 1.03 0.01 to 108 | 0.91 0.00 to 595 | 0.74 0.01 to 55.20 | 0.61 0.01 to 43.35 | 0.60 0.00 to 59.66 | 0.52 0.01 to 37.60 | 0.47 0.00 to 42.06 | 0.44 0.00 to 31.98 | 0.41 0.00 to 33.14 | 0.33 0.00 to 24.18 | 0.32 0.00 to 27.23 | 0.31 0.00 to 26.58 | 0.27 0.00 to 27.05 | 0.24 0.00 to 21.24 | 0.13 0.00 to 29.15 |
| TIRZ_SC_15MG_QW | 0.66 0.10 to 3.40 | 1.81 0.02 to 175 | 1.60 0.03 to 163 | 1.59 0.02 to 163 | 1.25 0.01 to 174 | 1.17 0.10 to 11.62 | 1.02 0.01 to 165 | 1.02 0.01 to 131 | 0.97 0.01 to 135 | TIRZ_SC_15MG_QW | 0.91 0.01 to 122 | 0.74 0.10 to 4.42 | 0.62 0.08 to 3.67 | 0.61 0.05 to 6.46 | 0.53 0.07 to 3.16 | 0.48 0.07 to 2.62 | 0.44 0.06 to 2.34 | 0.42 0.04 to 2.92 | 0.34 0.05 to 1.90 | 0.32 0.03 to 2.57 | 0.32 0.03 to 2.43 | 0.28 0.04 to 1.54 | 0.24 0.02 to 2.02 | 0.13 0.00 to 5.62 |
| TIRZ_SC_1MG_QW | 0.70 0.01 to 42.79 | 1.93 0.00 to 876 | 1.73 0.00 to 651 | 1.72 0.00 to 680 | 1.31 0.00 to 717 | 1.26 0.01 to 110 | 1.08 0.00 to 492 | 1.09 0.00 to 507 | 1.10 0.00 to 530 | 1.10 0.01 to 97.66 | TIRZ_SC_1MG_QW | 0.79 0.01 to 51.05 | 0.65 0.01 to 43.36 | 0.64 0.00 to 60.94 | 0.56 0.00 to 36.63 | 0.50 0.00 to 40.25 | 0.47 0.00 to 29.80 | 0.43 0.00 to 32.85 | 0.36 0.00 to 23.43 | 0.35 0.00 to 26.88 | 0.34 0.00 to 26.24 | 0.30 0.00 to 23.52 | 0.26 0.00 to 21.01 | 0.14 0.00 to 29.66 |
| ALBI_SC_FLEX_30-50_QW | 0.88 0.42 to 1.82 | 2.57 0.05 to 200 | 2.22 0.05 to 177 | 2.20 0.05 to 177 | 1.78 0.02 to 182 | 1.60 0.31 to 8.85 | 1.40 0.02 to 178 | 1.38 0.02 to 148 | 1.35 0.02 to 130 | 1.34 0.23 to 10.34 | 1.26 0.02 to 160 | ALBI_SC_FLEX_30-50_QW | 0.82 0.34 to 2.25 | 0.81 0.14 to 5.29 | 0.71 0.26 to 1.96 | 0.64 0.13 to 3.53 | 0.59 0.22 to 1.81 | 0.56 0.16 to 2.00 | 0.46 0.16 to 1.28 | 0.43 0.11 to 1.85 | 0.42 0.11 to 1.76 | 0.38 0.07 to 2.09 | 0.33 0.08 to 1.53 | 0.18 0.01 to 5.53 |
| LIRA_SC_1p8MG_QD | 1.07 0.53 to 1.87 | 3.03 0.06 to 231 | 2.73 0.06 to 211 | 2.61 0.06 to 200 | 2.11 0.02 to 213 | 1.93 0.41 to 9.22 | 1.66 0.02 to 199 | 1.66 0.02 to 169 | 1.64 0.02 to 162 | 1.61 0.27 to 12.07 | 1.54 0.02 to 186 | 1.23 0.44 to 2.92 | LIRA_SC_1p8MG_QD | 0.97 0.19 to 5.81 | 0.87 0.32 to 2.14 | 0.76 0.16 to 4.00 | 0.71 0.28 to 1.89 | 0.68 0.22 to 2.01 | 0.56 0.19 to 1.41 | 0.53 0.15 to 1.88 | 0.51 0.15 to 1.79 | 0.45 0.09 to 2.31 | 0.40 0.10 to 1.52 | 0.22 0.01 to 6.21 |
| DULA_SC_0p75MG_QW | 1.08 0.19 to 5.38 | 2.96 0.04 to 326 | 2.73 0.04 to 243 | 2.55 0.04 to 257 | 2.13 0.02 to 262 | 1.99 0.30 to 11.94 | 1.64 0.02 to 261 | 1.67 0.02 to 218 | 1.67 0.02 to 213 | 1.64 0.15 to 20.44 | 1.55 0.02 to 239 | 1.24 0.19 to 7.07 | 1.03 0.17 to 5.34 | DULA_SC_0p75MG_QW | 0.88 0.13 to 5.07 | 0.78 0.09 to 7.16 | 0.73 0.11 to 4.43 | 0.69 0.15 to 2.51 | 0.57 0.08 to 3.44 | 0.55 0.12 to 1.98 | 0.53 0.12 to 1.94 | 0.46 0.05 to 4.06 | 0.41 0.08 to 1.70 | 0.22 0.01 to 9.15 |
| DULA_SC_1p5MG_QW | 1.23 0.59 to 2.50 | 3.49 0.06 to 281 | 3.14 0.07 to 227 | 3.03 0.07 to 255 | 2.48 0.02 to 259 | 2.24 0.43 to 12.86 | 1.95 0.02 to 236 | 1.91 0.03 to 208 | 1.92 0.03 to 186 | 1.88 0.32 to 14.44 | 1.78 0.03 to 229 | 1.40 0.51 to 3.87 | 1.15 0.47 to 3.14 | 1.14 0.20 to 7.63 | DULA_SC_1p5MG_QW | 0.89 0.18 to 5.03 | 0.82 0.30 to 2.52 | 0.78 0.22 to 2.79 | 0.64 0.21 to 1.81 | 0.61 0.15 to 2.62 | 0.59 0.15 to 2.56 | 0.53 0.10 to 2.97 | 0.46 0.11 to 2.22 | 0.25 0.01 to 7.75 |
| TIRZ_SC_10MG_QW | 1.38 0.28 to 5.81 | 3.90 0.06 to 375 | 3.52 0.06 to 323 | 3.37 0.05 to 327 | 2.78 0.02 to 321 | 2.52 0.29 to 21.94 | 2.18 0.02 to 319 | 2.11 0.02 to 264 | 2.12 0.02 to 253 | 2.10 0.38 to 14.58 | 1.99 0.02 to 244 | 1.57 0.28 to 7.72 | 1.31 0.25 to 6.20 | 1.28 0.14 to 11.59 | 1.13 0.20 to 5.64 | TIRZ_SC_10MG_QW | 0.92 0.21 to 3.89 | 0.87 0.13 to 5.17 | 0.72 0.14 to 3.39 | 0.68 0.09 to 4.68 | 0.66 0.09 to 4.44 | 0.59 0.13 to 2.73 | 0.52 0.07 to 3.77 | 0.28 0.01 to 11.28 |
| SEMA_SC_1p0MG_QW | 1.50 0.66 to 3.01 | 4.22 0.08 to 326 | 3.74 0.09 to 293 | 3.64 0.08 to 290 | 2.97 0.03 to 297 | 2.70 0.48 to 15.16 | 2.35 0.03 to 280 | 2.37 0.03 to 244 | 2.29 0.03 to 226 | 2.26 0.43 to 15.88 | 2.13 0.03 to 255 | 1.71 0.55 to 4.65 | 1.40 0.53 to 3.64 | 1.38 0.23 to 9.02 | 1.22 0.40 to 3.32 | 1.09 0.26 to 4.83 | SEMA_SC_1p0MG_QW | 0.95 0.25 to 3.46 | 0.79 0.32 to 1.58 | 0.74 0.17 to 3.08 | 0.72 0.17 to 3.05 | 0.64 0.15 to 2.80 | 0.56 0.12 to 2.47 | 0.31 0.01 to 8.92 |
| SEMA_PO_14MG_QD | 1.55 0.53 to 4.63 | 4.40 0.08 to 404 | 4.05 0.08 to 337 | 3.93 0.08 to 333 | 3.15 0.03 to 357 | 2.82 0.91 to 10.15 | 2.44 0.03 to 319 | 2.45 0.03 to 290 | 2.45 0.03 to 264 | 2.38 0.34 to 22.32 | 2.32 0.03 to 297 | 1.80 0.50 to 6.06 | 1.47 0.50 to 4.58 | 1.44 0.40 to 6.71 | 1.29 0.36 to 4.52 | 1.14 0.19 to 7.50 | 1.05 0.29 to 3.99 | SEMA_PO_14MG_QD | 0.82 0.21 to 3.03 | 0.78 0.37 to 1.64 | 0.76 0.36 to 1.58 | 0.67 0.11 to 4.48 | 0.59 0.25 to 1.42 | 0.32 0.01 to 10.49 |
| SEMA_SC_0p5MG_QW | 1.91 0.93 to 4.22 | 5.57 0.10 to 439 | 4.85 0.11 to 409 | 4.84 0.10 to 387 | 3.93 0.04 to 421 | 3.49 0.66 to 20.78 | 3.05 0.04 to 370 | 2.98 0.04 to 322 | 3.04 0.04 to 306 | 2.95 0.53 to 21.76 | 2.77 0.04 to 356 | 2.18 0.78 to 6.43 | 1.79 0.71 to 5.31 | 1.76 0.29 to 12.60 | 1.55 0.55 to 4.87 | 1.40 0.29 to 7.40 | 1.27 0.63 to 3.09 | 1.21 0.33 to 4.73 | SEMA_SC_0p5MG_QW | 0.96 0.22 to 4.29 | 0.93 0.22 to 4.13 | 0.84 0.17 to 4.35 | 0.72 0.15 to 3.47 | 0.40 0.01 to 11.97 |
| SEMA_PO_7MG_QD | 2.00 0.57 to 7.10 | 5.64 0.10 to 533 | 5.10 0.10 to 434 | 4.96 0.10 to 447 | 4.08 0.03 to 476 | 3.64 0.92 to 14.96 | 3.16 0.04 to 438 | 3.13 0.04 to 375 | 3.11 0.04 to 359 | 3.08 0.39 to 30.55 | 2.88 0.04 to 397 | 2.30 0.54 to 9.15 | 1.89 0.53 to 6.86 | 1.83 0.50 to 8.44 | 1.64 0.38 to 6.66 | 1.47 0.21 to 10.55 | 1.35 0.33 to 5.98 | 1.28 0.61 to 2.71 | 1.04 0.23 to 4.55 | SEMA_PO_7MG_QD | 0.97 0.48 to 1.98 | 0.86 0.12 to 6.30 | 0.75 0.32 to 1.84 | 0.41 0.01 to 13.89 |
| SEMA_PO_3MG_QD | 2.05 0.60 to 7.09 | 5.86 0.10 to 562 | 5.34 0.10 to 480 | 5.12 0.10 to 445 | 4.18 0.04 to 463 | 3.74 0.97 to 15.78 | 3.25 0.04 to 425 | 3.16 0.04 to 394 | 3.22 0.04 to 361 | 3.12 0.41 to 30.32 | 2.98 0.04 to 400 | 2.37 0.57 to 9.35 | 1.94 0.56 to 6.75 | 1.88 0.51 to 8.65 | 1.69 0.39 to 6.76 | 1.51 0.23 to 11.20 | 1.39 0.33 to 5.95 | 1.31 0.63 to 2.76 | 1.08 0.24 to 4.57 | 1.03 0.51 to 2.08 | SEMA_PO_3MG_QD | 0.90 0.13 to 6.26 | 0.77 0.33 to 1.85 | 0.42 0.01 to 14.56 |
| TIRZ_SC_5MG_QW | 2.35 0.48 to 10.40 | 6.66 0.10 to 618 | 6.05 0.10 to 570 | 5.73 0.10 to 559 | 4.76 0.04 to 547 | 4.29 0.49 to 36.40 | 3.68 0.04 to 521 | 3.66 0.04 to 502 | 3.71 0.04 to 479 | 3.53 0.65 to 25.63 | 3.39 0.04 to 455 | 2.66 0.48 to 13.48 | 2.20 0.43 to 11.19 | 2.16 0.25 to 20.25 | 1.90 0.34 to 10.00 | 1.71 0.37 to 7.91 | 1.57 0.36 to 6.86 | 1.48 0.22 to 8.96 | 1.20 0.23 to 5.91 | 1.16 0.16 to 8.09 | 1.11 0.16 to 7.82 | TIRZ_SC_5MG_QW | 0.87 0.12 to 6.43 | 0.48 0.01 to 19.24 |
| SITAGLIPTIN | 2.66 0.69 to 9.77 | 7.46 0.12 to 735 | 6.82 0.13 to 589 | 6.52 0.12 to 618 | 5.37 0.05 to 626 | 4.88 1.14 to 21.72 | 4.14 0.05 to 574 | 4.16 0.05 to 480 | 4.23 0.05 to 478 | 4.10 0.49 to 42.07 | 3.84 0.05 to 535 | 3.05 0.65 to 12.96 | 2.52 0.66 to 9.66 | 2.47 0.59 to 12.54 | 2.19 0.45 to 9.00 | 1.92 0.27 to 15.05 | 1.77 0.40 to 8.25 | 1.71 0.70 to 3.92 | 1.39 0.29 to 6.47 | 1.34 0.54 to 3.08 | 1.30 0.54 to 3.03 | 1.16 0.16 to 8.60 | SITAGLIPTIN | 0.55 0.02 to 18.45 |
| SEMA_SC_16MG_QW | 4.89 0.17 to 137 | 13.75 0.08 to 2878 | 11.17 0.18 to 2643 | 11.55 0.15 to 1907 | 10.13 0.03 to 2640 | 8.96 0.23 to 351 | 8.02 0.03 to 2529 | 7.83 0.03 to 2176 | 7.65 0.03 to 2474 | 7.48 0.18 to 377 | 7.13 0.03 to 2496 | 5.57 0.18 to 166 | 4.62 0.16 to 133 | 4.64 0.11 to 197 | 3.98 0.13 to 123 | 3.60 0.09 to 139 | 3.26 0.11 to 103 | 3.16 0.10 to 102 | 2.52 0.08 to 77.00 | 2.46 0.07 to 84.77 | 2.38 0.07 to 84.22 | 2.08 0.05 to 89.18 | 1.83 0.05 to 66.31 | SEMA_SC_16MG_QW |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteOutcome assessment, time point: selected time points span 5 to 365.26 weeks
- NoteOutcome assessment, analysis set: mixed: full_analysis 1, other 1, randomized 3, safety 11
- NoteOutcome assessment, definition: mixed: EAC confirmed acute pancreatitis 1, EAC confirmed retinopathy complications: photocoagulation, intravitreal agents, vitreous hemorrhage or diabetes related blindness 1, hypoglycemia requiring medical assistance 1, in trial adverse events related to diabetic retinopathy by MedDRA search 1, not stated 10, Retinopathy composite of the trial 1, severe hypoglycemic events, adverse event of special interest 1
- NoteOutcome assessment, adjudicated: mixed: no 1, not stated 9, yes 6
- NoteOutcome assessment, proportion method: mixed: not stated 15, observed 1
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 13, treatment_policy 2, while_on_treatment 1
- NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 15, treatment_policy 1
- NoteRisk of bias, blinding: mixed: double_blind 11, open_label 1, single_blind 4
- NoteRisk of bias, funding: mixed: industry 14, non_industry 2
- NoteData handling, input conversions: count_from_percent 4, printed_denominator 1
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | 30 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2017 | age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin |
| SURPASS-2 | 44 | safety | not stated | not stated | not stated | not stated | not stated | not stated | single_blind | industry | 2019 | age 18 or older, HbA1c 7.0 to 10.5 percent, BMI 25 or more, metformin 1500 mg/day or more, eGFR 45 or more |
| PIONEER 4 | 57 | safety | in trial adverse events related to diabetic retinopathy by MedDRA search | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2016 | Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more |
| REWIND | 365.26 | randomized | not stated | not stated | yes | not stated | treatment_policy | not stated | double_blind | industry | 2011 | age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors |
| PIONEER 10 | 57 | safety | not stated | not stated | yes | not stated | while_on_treatment | treatment_policy | single_blind | industry | 2017 | Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug |
| PIONEER 2 | 57 | safety | not stated | not stated | not stated | not stated | treatment_policy | not stated | single_blind | industry | 2016 | type 2 diabetes on metformin; HbA1c 7.0 to 10.5 percent; eGFR 60 or more |
| STARDUST | 26.07 | safety | not stated | not stated | not stated | not stated | not stated | not stated | single_blind | non_industry | 2021 | age 35 or older, T2D with PAD, foot TcPO2 30 to 49 mmHg, HbA1c 6.5 to 8 percent |
| PIONEER 12 | 31 | other | EAC confirmed acute pancreatitis | not stated | yes | not stated | not stated | not stated | double_blind | industry | 2019 | adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent |
| NCT02465515 | 140.89 | safety | severe hypoglycemic events, adverse event of special interest | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2015 | type 2 diabetes with established cardiovascular disease |
| LEADER® | 264.99 | randomized | Retinopathy composite of the trial | not stated | not stated | observed | not stated | not stated | double_blind | industry | 2010 | T2D HbA1c 7.0 or more; age 50 or more with CVD, CKD stage 3 or more or HF, or age 60 or more with CV risk factors |
| NCT05486065 | 49 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin |
| SURMOUNT-2 | 76 | randomized | not stated | not stated | yes | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 or older; BMI 27 or more; type 2 diabetes with HbA1c 7 to 10 percent on diet or oral drugs |
| SUSTAIN™ 5 | 35 | safety | not stated | not stated | yes | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more |
| SUSTAIN™ 6 | 109 | full_analysis | EAC confirmed retinopathy complications: photocoagulation, intravitreal agents, vitreous hemorrhage or diabetes related blindness | not stated | yes | not stated | not stated | not stated | double_blind | industry | 2013 | T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor |
| S002947 | 25 | safety | not stated | not stated | no | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out |
| S003079 | 5 | safety | hypoglycemia requiring medical assistance | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | 2010 | age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | A1 | PLACEBO | 30 | arm, events | 0 / 51 | R0016215:Results | |||
| NCT03131687 | A2 | TIRZ_SC_1MG_QW | 30 | arm, events | 0 / 53 | R0016215:Results | |||
| NCT03131687 | A3 | TIRZ_SC_5MG_QW | 30 | arm, events | 0 / 55 | R0016215:Results | |||
| NCT03131687 | A4 | TIRZ_SC_10MG_QW | 30 | arm, events | 0 / 52 | R0016215:Results | |||
| NCT03131687 | A5 | TIRZ_SC_15MG_QW | 30 | arm, events | 0 / 53 | R0016215:Results | |||
| NCT03131687 | A6 | DULA_SC_1p5MG_QW | 30 | arm, events | 0 / 54 | R0016215:Results | |||
| SURPASS-2 | A1 | TIRZ_SC_5MG_QW | 44 | arm, events | 5 / 471 | R0013656:Supplement Table S12 | |||
| SURPASS-2 | A2 | TIRZ_SC_10MG_QW | 44 | arm, events | 3 / 469 | R0013656:Supplement Table S12 | |||
| SURPASS-2 | A3 | TIRZ_SC_15MG_QW | 44 | arm, events | 2 / 470 | R0013656:Supplement Table S12 | |||
| SURPASS-2 | A4 | SEMA_SC_1p0MG_QW | 44 | arm, events | 2 / 469 | R0013656:Supplement Table S12 | |||
| PIONEER 4 | A1 | SEMA_PO_14MG_QD | 57 | arm, events | 8 / 285 | R0015836:Supplement Table S7 | |||
| PIONEER 4 | A2 | LIRA_SC_1p8MG_QD | 57 | arm, events | 4 / 284 | R0015836:Supplement Table S7 | |||
| PIONEER 4 | A3 | PLACEBO | 57 | arm, events | 2 / 142 | R0015836:Supplement Table S7 | |||
| REWIND | A1 | PLACEBO | 365.26 | arm, events | 76 / 4,952 | R0018537:Table 2 | |||
| REWIND | A2 | DULA_SC_1p5MG_QW | 365.26 | arm, events | 95 / 4,949 | R0018537:Table 2 | |||
| PIONEER 10 | A1 | SEMA_PO_3MG_QD | 57 | arm, events | 9 / 131 | R0018421:Table 2 | |||
| PIONEER 10 | A2 | SEMA_PO_7MG_QD | 57 | arm, events | 12 / 132 | R0018421:Table 2 | |||
| PIONEER 10 | A3 | SEMA_PO_14MG_QD | 57 | arm, events | 7 / 130 | R0018421:Table 2 | |||
| PIONEER 10 | A4 | DULA_SC_0p75MG_QW | 57 | arm, events | 3 / 65 | R0018421:Table 2 | |||
| PIONEER 2 | A1 | SEMA_PO_14MG_QD | 57 | arm, events | 14 / 412 | R0018256:Supplement Table S5 | |||
| PIONEER 2 | A2 | EMPAGLIFLOZIN | 57 | arm, events | 5 / 410 | R0018256:Supplement Table S5 | |||
| STARDUST | A1 | LIRA_SC_1p8MG_QD | 26.07 | arm, events | 0 / 30 | registry:adverse_events | |||
| STARDUST | A2 | STANDARD_CARE | 26.07 | arm, events | 0 / 30 | registry:adverse_events | |||
| PIONEER 12 | A1 | SEMA_PO_3MG_QD | 31 | arm, events | 17 / 361 | R0019776:Results | |||
| PIONEER 12 | A2 | SEMA_PO_7MG_QD | 31 | arm, events | 13 / 360 | R0019776:Results | |||
| PIONEER 12 | A3 | SEMA_PO_14MG_QD | 31 | arm, events | 12 / 361 | R0019776:Results | |||
| PIONEER 12 | A4 | SITAGLIPTIN | 31 | arm, events | 20 / 359 | R0019776:Results | |||
| NCT02465515 | A1 | PLACEBO | 140.89 | arm, events | 89 / 4,732 | registry:outcomes | |||
| NCT02465515 | A2 | ALBI_SC_FLEX_30-50_QW | 140.89 | arm, events | 78 / 4,731 | registry:outcomes | |||
| LEADER® | A1 | LIRA_SC_1p8MG_QD | 264.99 | arm, events | 107 / 4,668 | count_from_percent | registry:outcomes | ||
| LEADER® | A2 | PLACEBO | 264.99 | arm, events | 93 / 4,672 | count_from_percent | registry:outcomes | ||
| NCT05486065 | A1 | SEMA_SC_2p0MG_QW | 49 | arm, events | 0 / 61 | R0005510:Table 2 | |||
| NCT05486065 | A2 | SEMA_SC_8MG_QW | 49 | arm, events | 0 / 62 | R0005510:Table 2 | |||
| NCT05486065 | A3 | SEMA_SC_16MG_QW | 49 | arm, events | 1 / 62 | R0005510:Table 2 | |||
| NCT05486065 | A4 | PLACEBO | 49 | arm, events | 0 / 60 | R0005510:Table 2 | |||
| SURMOUNT-2 | A1 | TIRZ_SC_10MG_QW | 76 | arm, events | 1 / 312 | R0008662:Table 3 | |||
| SURMOUNT-2 | A2 | TIRZ_SC_15MG_QW | 76 | arm, events | 0 / 311 | R0008662:Table 3 | |||
| SURMOUNT-2 | A3 | PLACEBO | 76 | arm, events | 1 / 315 | R0008662:Table 3 | |||
| SUSTAIN™ 5 | A1 | SEMA_SC_0p5MG_QW | 35 | arm, events | 4 / 132 | count_from_percent | R0012671:Results | ||
| SUSTAIN™ 5 | A2 | SEMA_SC_1p0MG_QW | 35 | arm, events | 1 / 132 | count_from_percent | R0012671:Results | ||
| SUSTAIN™ 5 | A3 | PLACEBO | 35 | arm, events | 0 / 133 | R0012671:Results | |||
| SUSTAIN™ 6 | A1 | SEMA_SC_0p5MG_QW | 109 | arm, events | 25 / 826 | R0020578:Results | |||
| SUSTAIN™ 6 | A2 | SEMA_SC_1p0MG_QW | 109 | arm, events | 25 / 822 | R0020578:Results | |||
| SUSTAIN™ 6 | A6 | PLACEBO | 109 | arm, events | 29 / 1,649 | printed_denominator | R0020578:Results | ||
| S002947 | A1 | ECNO_SC_0p4MG_QW | 25 | arm, events | 0 / 37 | R0006482:Results | |||
| S002947 | A2 | ECNO_SC_0p8MG_QW | 25 | arm, events | 0 / 36 | R0006482:Results | |||
| S002947 | A3 | ECNO_SC_1p2MG_QW | 25 | arm, events | 0 / 36 | R0006482:Results | |||
| S002947 | A4 | PLACEBO | 25 | arm, events | 0 / 36 | R0006482:Results | |||
| S003079 | A1 | EXEN_SC_10UG_BID | 5 | arm, events | 0 / 18 | R0025923:Results | |||
| S003079 | A2 | STANDARD_CARE | 5 | arm, events | 0 / 18 | R0025923:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.